Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic innervations in central nervous system that resu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2011-12-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/5298 |
| _version_ | 1797204647770849280 |
|---|---|
| author | O A Gerasimenko E Pigarova L K Dzeranova |
| author_facet | O A Gerasimenko E Pigarova L K Dzeranova |
| author_sort | O A Gerasimenko |
| collection | DOAJ |
| description | Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic innervations in central nervous system that results in decrease of postprandial glucose. Bromocriptine decreases hepatic glucose production and increases insulin secretion and muscle insulin sensitivity. This article reviews experimental and clinical data on the use of bromocriptine for treatment of type 2 diabetes mellitus |
| first_indexed | 2024-03-08T09:13:51Z |
| format | Article |
| id | doaj.art-0b82fce016f94715bf521f516921139f |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2024-04-24T08:38:33Z |
| publishDate | 2011-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-0b82fce016f94715bf521f516921139f2024-04-16T16:16:06ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242011-12-0184162210.14341/2071-8713-52985256Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2O A Gerasimenko0E Pigarova1L K Dzeranova2<p>Endocrinology Research Centre, Moscow</p><p>Endocrinology Research Centre, Moscow</p><p>Endocrinology Research Centre, Moscow</p>Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic innervations in central nervous system that results in decrease of postprandial glucose. Bromocriptine decreases hepatic glucose production and increases insulin secretion and muscle insulin sensitivity. This article reviews experimental and clinical data on the use of bromocriptine for treatment of type 2 diabetes mellitushttps://www.omet-endojournals.ru/jour/article/view/5298bromocriptinediabetes mellitus type 2insulindopamine |
| spellingShingle | O A Gerasimenko E Pigarova L K Dzeranova Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 Ожирение и метаболизм bromocriptine diabetes mellitus type 2 insulin dopamine |
| title | Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 |
| title_full | Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 |
| title_fullStr | Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 |
| title_full_unstemmed | Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 |
| title_short | Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 |
| title_sort | dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2 |
| topic | bromocriptine diabetes mellitus type 2 insulin dopamine |
| url | https://www.omet-endojournals.ru/jour/article/view/5298 |
| work_keys_str_mv | AT oagerasimenko dopaminergicagonistbromocriptinintreatmentofdiabetesmellitustype2 AT epigarova dopaminergicagonistbromocriptinintreatmentofdiabetesmellitustype2 AT lkdzeranova dopaminergicagonistbromocriptinintreatmentofdiabetesmellitustype2 |